Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Question for Whalewatcher

<< Previous

Bullboard Posts

Next >>

Comment by Whalewatcher1on Dec 28, 2021 5:40pm

90 Views

Post# 34266142

RE:RE:RE:RE:Question for Whalewatcher

I could be wrong. But if you go look up for youself how stocks trade post Nasdaq listing. CSE/TSXV listed stocks never double or so just because they list on Nasdaq . . . We both agree that they need $15M US market cap. I just dont believe that management has a proper grasp on the steps/requiremetns to uplist and becomes another example of setting guidance that cant be reallistically achieved.

<< Previous

Bullboard Posts

Next >>

Cybin launches new program phase to treat Major Depressive Disorder